FORT WORTH, Texas, March 31 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary Wound Care Innovations, LLC launched a new section for patients on their CellerateRx® web site. The new area of the web site is intended to help diabetic patients learn how the advanced wound care collagen product, CellerateRx®, may help them. It focuses on information for home diabetic patients that have acute or chronic diabetic wounds and are looking for a safe, effective, easy to use product. It provides easy to understand product information and application guidelines. It also has an area to print product information to take to a healthcare provider.
"We are excited about launching our web site's new patient section with information about diabetic wounds," states Cathy Bradshaw, President of Wound Care Innovations. "One in six people with diabetes will develop a foot ulcer during their lifetime. These ulcers are the leading cause of hospitalization among diabetic patients and often lead to amputation. We have a product that has been shown to be effective in the management of these diabetic wounds and are delighted to be able to present the information specifically for the patient with diabetes at home who is looking for a safe and effective product."
Wound Care Innovations also announced its first newsletter, Activated Collagen™ News. This reoccurring newsletter features up to date information about diabetes and other wound types, as well as a segment "Meet the Wound Care Expert." One area will focus on patient specific experiences with CellerateRx®. This issue features a patient who had a non-healing wound for ten (10) years prior to using CellerateRx®. The newsletter can be found on the www.celleraterx.com web site under the About Us Section.
"The newsletter is a great tool for us to communicate with our customers," states Cathy Bradshaw. "We will provide up to date information on our products, wound care, and company activities. We are particularly excited about sharing patient experiences with CellerateRx®."
For Wound Management Technologies Shareholder Information please call 561-515-6035 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRx, please visit the WCI web site at www.Celleraterx.com .
About Wound Management Technologies, Inc.
Wound Management Technologies Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: www.wmgtech.com, www.CellerateRX.com , and www.SecureeHealth.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications -561-515-6035
SOURCE Wound Management Technologies, Inc.
Advertisement
"We are excited about launching our web site's new patient section with information about diabetic wounds," states Cathy Bradshaw, President of Wound Care Innovations. "One in six people with diabetes will develop a foot ulcer during their lifetime. These ulcers are the leading cause of hospitalization among diabetic patients and often lead to amputation. We have a product that has been shown to be effective in the management of these diabetic wounds and are delighted to be able to present the information specifically for the patient with diabetes at home who is looking for a safe and effective product."
Advertisement
Wound Care Innovations also announced its first newsletter, Activated Collagen™ News. This reoccurring newsletter features up to date information about diabetes and other wound types, as well as a segment "Meet the Wound Care Expert." One area will focus on patient specific experiences with CellerateRx®. This issue features a patient who had a non-healing wound for ten (10) years prior to using CellerateRx®. The newsletter can be found on the www.celleraterx.com web site under the About Us Section.
"The newsletter is a great tool for us to communicate with our customers," states Cathy Bradshaw. "We will provide up to date information on our products, wound care, and company activities. We are particularly excited about sharing patient experiences with CellerateRx®."
For Wound Management Technologies Shareholder Information please call 561-515-6035 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRx, please visit the WCI web site at www.Celleraterx.com .
About Wound Management Technologies, Inc.
Wound Management Technologies Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: www.wmgtech.com, www.CellerateRX.com , and www.SecureeHealth.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications -561-515-6035
SOURCE Wound Management Technologies, Inc.
